These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 18559761

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
    Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I.
    Eur J Cancer; 2009 Nov; 45(17):2930-4. PubMed ID: 19767198
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F.
    Oncology; 2009 Nov; 76(1):49-54. PubMed ID: 19039248
    [Abstract] [Full Text] [Related]

  • 26. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, Latreille J, Vandenberg T, Goel R, Zibdawi L, Rahim Y, Pouliot JF.
    J Clin Oncol; 2009 Dec 10; 27(35):5906-10. PubMed ID: 19858391
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome.
    Klemke CD, Mansmann U, Poenitz N, Dippel E, Goerdt S.
    Br J Dermatol; 2005 Jul 10; 153(1):118-24. PubMed ID: 16029336
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
    Fujisaka Y, Horiike A, Shimizu T, Yamamoto N, Yamada Y, Tamura T.
    Jpn J Clin Oncol; 2006 Dec 10; 36(12):768-74. PubMed ID: 17095524
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.
    Harrison LE, Bryan M, Pliner L, Saunders T.
    Ann Surg Oncol; 2008 May 10; 15(5):1407-13. PubMed ID: 18157576
    [Abstract] [Full Text] [Related]

  • 34. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
    Pectasides D, Pectasides E, Papaxoinis G, Xiros N, Sykiotis C, Papachristodoulou A, Tountas N, Panayiotides J, Economopoulos T.
    Gynecol Oncol; 2008 Sep 10; 110(3):299-303. PubMed ID: 18602677
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M.
    Am J Clin Oncol; 2008 Oct 10; 31(5):476-80. PubMed ID: 18838885
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
    Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M.
    J Clin Oncol; 2007 Sep 20; 25(27):4293-7. PubMed ID: 17709797
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.